Tag: Regulatory

CHARLOTTE, N.C., June 16, 2026 /PRNewswire/ -- Greenland Mines Ltd ("Greenland Mines" or the "Company") (Nasdaq: GRML) is pleased to announce that it has...

Wheel of Fortune TRIO Player Takes Home More Than $596,000 in Combined Progressive JackpotsOHKAY OWINGEH, N.M., June 16, 2026 /PRNewswire/ -- A guest at...

NASDAQ: EUTSXV: EUwww.encoreuranium.comDALLAS, June 16, 2026 /PRNewswire/ - enCore Energy Corp. (NASDAQ: EU) (TSXV: EU) (the "Company" or "enCore"), America's Clean Energy CompanyTM, reports positive...

Complementary upstream and downstream capabilities to enhance integration and enable the combined company to better create value across cycles, products and regions $400+ million...

TSX: TVECALGARY, AB, June 16, 2026 /CNW/ - Tamarack Valley Energy Ltd. has successfully closed the previously announced sale of its Charlie Lake assets for...

Next-generation semantic intelligence platform accelerates enterprise AI modernization by 3X while ensuring strict compliance for regulated industries.LONDON, June 16, 2026 /PRNewswire/ -- Onix today...

Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to an additional 3,400,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Before deducting the underwriting discounts and commissions and offering expenses, the Company expects to receive total gross proceeds of approximately $85 million from the Offering, or approximately $98 million if the underwriters exercise in full their option to purchase additional shares.

MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye diseaseAt 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at...

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”), of the important June 23, 2026 lead plaintiff deadline.

DERM Zero is a world-first - using Class III regulated medical device1 technology to deliver autonomous clinical grade skin cancer assessments from a standard...

Terra Innovatum Global N.V. (NASDAQ: NKLR) Files 2025 Form 10‑k and Reports Fourth Quarter and Fiscal Year 2025 Financial Results

VANCOUVER, British Columbia, June 15, 2026 (GLOBE NEWSWIRE) -- Central 1 Credit Union (Central 1) today announced that on June 30, 2026 it will redeem at par all of its issued and outstanding Series 7 Subordinated Notes due on June 30, 2031 (the Notes).